Le Lézard
Classified in: Health
Subjects: CCA, FVT

Evolent Health to Participate in Upcoming Investor Conference


WASHINGTON, Nov. 20, 2019 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company providing an integrated value-based care platform to the nation's leading provider and payer organizations, today announced that Chief Executive Officer and Co-Founder Frank Williams, President and Co-Founder Seth Blackley, and Chief Financial Officer John Johnson will participate in an upcoming investor conference.

Evolent Health Logo (PRNewsfoto/Evolent Health)

About Evolent Health
Evolent Health partners with leading provider and payer organizations to achieve superior clinical and financial results in value-based care and under full-risk arrangements. With a provider heritage and over 20 years of health plan administration experience, Evolent partners with more than 35 health care organizations to actively manage care across Medicare, Medicaid, commercial and self-funded adult and pediatric populations. With the experience to drive change, Evolent confidently stands by a commitment to achieve results. For more information, visit evolenthealth.com.

Contacts:

Bob East or Asher Dewhurst
443.213.0500
Investor Relations
InvestorRelations@evolenthealth.com

SOURCE Evolent Health, Inc.


These press releases may also interest you

at 02:05
The Healthcare Information and Management Systems Society (HIMSS) and Elsevier, the global information analytics business specializing in science and health, are proud to announce the call for submissions for the Annual HIMSS-Elsevier Digital...

at 01:05
Regulatory News: Lysogene (Paris:LYS) (FR0013233475 ? LYS) today announced its corporate agenda* for 2020: 17 February 2020: Sales and cash position at the end of 2019 20 March 2020: 2019 annual results 22 April 2020: First...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of...

at 01:05
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia...

at 01:04
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient in Australia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib,...

23 jan 2020
Sasakawa Health Foundation has announced the start of its first-ever social media campaign with organizations of persons affected by leprosy. Taking part are 17 people's organizations in 16 countries that are linking up...



News published on 20 november 2019 at 14:00 and distributed by: